AMGN

Amgen Inc.

Next est. report 2026-08-04 · AMC

GLP-1 Long '24: GLP1 Drug Producer MedTech Short '25: Heavy China ExposureSmall Themes '25: Ghost Nations

Loading…

Overview

Amgen Inc. is a global biotechnology company that discovers, develops, and delivers human medicines for serious illnesses across areas like inflammation, oncolo

Amgen Inc. is a global biotechnology company that discovers, develops, and delivers human medicines for serious illnesses across areas like inflammation, oncology, bone health, and cardiovascular diseases. Its portfolio includes innovative drugs and biosimilars, with six key growth drivers representing nearly 70% of sales. Amgen sells primarily to healthcare providers, hospitals, and pharmacies, increasingly expanding direct-to-patient access.

What They Do (Plain English & Analogies): Amgen is a leading biotechnology company that discovers, develops, manufactures, and delivers innovative human medicines for people with serious illnesses. Think of them as a highly specialized research and development lab that creates complex biological drugs, often made from living cells, to target specific problems in the body. They focus on critical areas like cancer, heart disease, bone problems, inflammatory conditions, and rare diseases where existing treatments are insufficient. Beyond developing new medicines, they also produce high-quality, more affordable versions of existing biological drugs, called biosimilars, to make important treatments accessible to more patients. They handle the entire process from scientific discovery and rigorous testing to large-scale manufacturing and global distribution to healthcare providers and patients.
Very Brief History: Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California. Over the decades, it has grown into a global biotechnology leader, consistently focusing on discovering, developing, manufacturing, and delivering human therapeutics across various therapeutic areas. Key milestones include the launch of numerous blockbuster drugs, continuous investment in a robust pipeline of innovative therapies and biosimilars, and strategic acquisitions like ChemoCentryx in 2022 and Horizon Therapeutics in 2023. The company has expanded its global reach and continues to evolve through strategic collaborations and significant R&D investments.
"Street Stereotype": Amgen is generally perceived by investors and analysts as a mature, large-cap biotechnology company with a strong, diversified portfolio of established blockbuster drugs and a significant presence in biosimilars, providing stable cash flow. However, it's also seen as a company with a promising late-stage pipeline, particularly in high-growth areas like obesity (with MariTide) and cardiovascular disease (with Olpasiran), which could drive future growth. There's an awareness of the ongoing challenge of biosimilar competition for some of its older, high-revenue products, necessitating continuous innovation and pipeline success to offset potential revenue erosion. The market is currently focused on the execution of its 'springboard year' objectives for 2026, driven by its key growth products and pipeline advancements, especially MariTide.
Subsidiaries On Linked In*: Amgen Canada Inc. — LinkedIn: Amgen-Canada
Amgen Fremont Inc.
Amgen Global Finance B.V.
Amgen International Holdings Inc.
Amgen K.K. — LinkedIn: Amgen-K.K.
Amgen K-A, Inc.
Amgen Mexico, S.A. de C.V. — LinkedIn: Amgen-Mexico
Amgen Rare Disease Holdings Inc.
Amgen S.A.S. — LinkedIn: Amgen-France
Amgen S.p.A. — LinkedIn: Amgen-Italy
Amgen Singapore Holding Pte. Ltd.
Amgen Singapore Manufacturing Pte. Ltd.
Amgen USA Inc.
Amgen Worldwide Holdings B.V.
Amgen, S.A. — LinkedIn: Amgen-Spain
ChemoCentryx, Inc. — Acquired by Amgen in 2022, maker of Tavneos; LinkedIn: ChemoCentryx
Five Prime Therapeutics, Inc. — Acquired by Amgen in 2021; LinkedIn: Five-Prime-Therapeutics
Horizon Therapeutics USA, Inc. — Acquired by Amgen in 2023; LinkedIn: Horizon-Therapeutics
Onyx Pharmaceuticals, Inc. — Acquired by Amgen; LinkedIn: Onyx-Pharmaceuticals
deCODE Genetics ehf — LinkedIn: deCODE-genetics
Viela Bio, Inc. — Acquired by Amgen in 2021; LinkedIn: Viela-Bio
Customer Sectors & Example Clients: Amgen primarily serves healthcare providers, including physicians and their clinics, dialysis centers, hospitals, and pharmacies. They also distribute through pharmaceutical wholesale distributors. Based on their business model and industry, example clients would include large healthcare systems (e.g., Kaiser Permanente), pharmacy benefit managers (e.g., CVS Health, Express Scripts), and various hospital networks. They are also expanding direct-to-consumer channels for certain products.
New Customers / Segments They'Re Targeting: Amgen is actively targeting several new customer segments and expanding its reach. For **MariTide**, they are focusing on patients with obesity, type 2 diabetes, and obesity-related conditions, including those who may wish to switch from weekly injectables to a less frequent dosing schedule (every 8- or 12-weeks). **Repatha** is expanding its reach into high-risk primary prevention patients, particularly those with diabetes but without known significant atherosclerosis, following updated ACC/AHA guidelines and new data. They are also offering a simplified cash-pay option in the U.S. to broaden access. For **EVENITY**, Amgen aims to treat the significant unmet need among the more than 90% of 2 million women at very high fracture risk who remain untreated. **TEZSPIRE** is expanding its patient population with a new indication for coexisting chronic rhinosinusitis with nasal polyps. **UPLIZNA** is targeting patients with generalized myasthenia gravis (gMG), including bio-naive and switch patients, and plans to initiate pivotal Phase III studies in autoimmune hepatitis and chronic inflammatory demyelinating polyneuropathy. **TEPEZZA** is looking to expand globally with additional launches in 2026 and beyond, and its on-body injector aims to enable administration at more sites of care. **IMDELLTRA** is being advanced into earlier lines of therapy for small cell lung cancer, moving beyond its current second-line standard of care. Finally, **Olpasiran** is targeting patients with elevated Lp(a), with new ACC/AHA lipid guidelines recommending broader Lp(a) testing, which will help identify more eligible patients.
Supply Chain And Sourcing Geographies: Amgen's supply chain involves significant manufacturing operations within the United States, including sites in Ohio, North Carolina, and Puerto Rico. They also have manufacturing facilities in Ireland, the Netherlands, and Singapore. The company has made substantial capital expenditures in 2026, approximately $2.6 billion, to scale manufacturing capacity for volume growth, including for MariTide's launch. These investments also cover sites in Rhode Island and California.
Sales Geographies And Expansion Plans: Amgen currently sells its products worldwide. Specific geographies mentioned in the transcript include the U.S. and Japan, where products like EVENITY have significant market share. The company is actively pursuing global expansion for several products. For instance, **TEPEZZA** expects additional global launches in 2026 and beyond, following its launch in Japan in 2025. **IMDELLTRA** is expected to launch in the second-line indication across multiple markets in 2026. **UPLIZNA** recently received European Commission approval for generalized myasthenia gravis.
How Key Themes May Help/Hurt: The 'GLP-1 Drug Producer' theme strongly benefits Amgen due to its rapidly advancing MariTide program. MariTide is positioned as a potentially paradigm-changing therapy for obesity, type 2 diabetes, and related conditions, offering strong efficacy, favorable tolerability, and a highly differentiated less-frequent dosing schedule (monthly, every 8- or 12-weeks). This directly aligns with the bull points of the GLP-1 theme, which emphasize strong clinical evidence, increased adoption, and the potential for improved patient compliance with novel formulations. The focus on long-term maintenance and switching from weekly injectables addresses key patient dissatisfaction points, potentially driving significant market penetration and sustained revenue streams for Amgen. The company's investment in scaling manufacturing capacity for MariTide's launch further underscores its commitment to capitalizing on this theme. While the theme's bear points mention increased competition and regulatory scrutiny, Amgen's strategy with MariTide focuses on differentiation through convenience and tolerability, aiming to carve out a significant market share despite existing players.

3 Main Long-Term Bull Details

Amgen's late-stage pipeline, particularly MariTide for obesity and type 2 diabetes, represents a potential paradigm shift with its differentiated profile of strong efficacy, favorable tolerability with 3-step dose escalation, and convenient every 8- or 12-week dosing, positioning it for significant long-term market adoption and a multi-billion dollar franchise.
The company's diversified portfolio of six key growth drivers (Repatha, EVENITY, TEZSPIRE, rare disease, innovative oncology, and biosimilars portfolios) continues to deliver robust performance, collectively generating 70% of sales and growing 24% year-over-year in Q1 2026, effectively offsetting patent expirations and underpinning sustained revenue expansion.
Amgen is strategically leveraging artificial intelligence and data science across its entire enterprise, accelerating R&D (e.g., 50% faster antibody lead optimization, up to threefold improvement in clinical trial enrollment) and optimizing manufacturing (e.g., reduced production line clearance time), which enhances long-term innovation, operational efficiency, and competitive advantage.

3 Main Long-Term Bear Details

Amgen anticipates accelerated sales erosion for key products like Prolia and Xgeva, which combined saw a 32% year-over-year decrease in Q1 2026, driven by increased competition from multiple biosimilars, necessitating continuous pipeline success to replace lost revenue.
Regulatory and pipeline risks persist, highlighted by the FDA's proposed withdrawal of TAVNEOS and the temporary pause in enrollment for subcutaneous BLINCYTO studies due to inflammatory reactions, alongside the discontinuation of AMG 193, underscoring inherent uncertainties in drug development.
Amgen faces substantial financial risk from ongoing tax litigation with the IRS for 2010-2015 and a new draft notice of proposed adjustment for 2016-2018, primarily related to profit allocation with Puerto Rico, which could result in material negative financial adjustments if not resolved favorably.

Competitors And Differentiation: Amgen faces competition across its diverse portfolio. For **Prolia and Xgeva**, they anticipate accelerated sales erosion due to increased competition from multiple biosimilars. In the **obesity/GLP-1 market**, MariTide aims to differentiate itself from existing weekly injectables (like semaglutide or tirzepatide) by offering less frequent dosing (monthly, every 8- or 12-weeks) and favorable tolerability, addressing treatment burden and persistence issues. **Repatha** is positioned as the only PCSK9 inhibitor with positive outcomes data in both high-risk primary and secondary prevention patients, giving it a unique advantage over competitors. For **Olpasiran**, it targets Lp(a), an independent risk factor that is not meaningfully reduced by GLP-1 medicines, statins, or PCSK9 inhibitors, thus offering a differentiated approach. In the **ANCA-associated vasculitis market**, TAVNEOS faces regulatory challenges, but Amgen believes it remains an important medicine with limited treatment options. In the **small cell lung cancer market**, IMDELLTRA is emerging as a standard of care in second-line extensive stage disease, delivering an unprecedented survival benefit. Amgen's biosimilar portfolio competes with innovator biologics and other biosimilar entrants, with PAVBLU gaining adoption due to its ready-to-use prefilled syringe and Amgen's manufacturing track record.
Recent Performance & What The Market'S Focused On: Amgen reported a strong first quarter of 2026, with overall product sales growing 4% year-over-year. The company's six key growth drivers collectively delivered 24% year-over-year sales growth, generating $5.6 billion in sales and representing almost 70% of total product sales. This performance led management to raise its 2026 guidance ranges for both revenue ($37.1 billion to $38.5 billion) and non-GAAP earnings per share ($21.70 to $23.10), reinforcing its outlook for 2026 as a 'springboard year'. The market is primarily focused on the continued momentum of these growth drivers, particularly the advancement of the MariTide program with its new Phase III studies and promising tolerability data, and the progress of other late-stage pipeline assets like Olpasiran and IMDELLTRA. Investors are also closely watching the resolution of the FDA's proposed withdrawal of TAVNEOS and the ongoing IRS tax litigation, which pose material financial risks. The integration of AI and data science across the company is also a key area of interest for its potential to drive long-term innovation and efficiency.

Revenue Segments And Estimated Mix: Innovative Oncology Portfolio — Mix: ~22.5%; Source: Q1 2026 sales of $1.8 billion out of ~$8 billion total product sales.; Trend: Grew 25% year-over-year in Q1 2026.
Rare Disease Portfolio — Mix: ~15%; Source: Q1 2026 sales of $1.2 billion out of ~$8 billion total product sales.; Trend: Grew 25% year-over-year in Q1 2026.
Biosimilars Portfolio — Mix: ~10.4%; Source: Q1 2026 sales of $835 million out of ~$8 billion total product sales.; Trend: Grew 14% year-over-year in Q1 2026.
Prolia and XGEVA (combined) — Mix: ~13.8%; Source: Q1 2026 sales of $1.1 billion out of ~$8 billion total product sales.; Trend: Decreased 32% year-over-year in Q1 2026; accelerated sales erosion expected over remainder of 2026.
Repatha — Mix: ~10.9%; Source: Q1 2026 sales of $876 million out of ~$8 billion total product sales.; Trend: Grew 34% year-over-year in Q1 2026.
EVENITY — Mix: ~7%; Source: Q1 2026 sales of $562 million out of ~$8 billion total product sales.; Trend: Increased 27% in Q1 2026.
TEPEZZA — Mix: ~6.1%; Source: Q1 2026 sales of $490 million out of ~$8 billion total product sales.; Trend: Grew 29% in Q1 2026.
TEZSPIRE — Mix: ~4.3%; Source: Q1 2026 sales of $343 million out of ~$8 billion total product sales.; Trend: Grew 20% year-over-year in Q1 2026.
UPLIZNA — Mix: ~3.3%; Source: Q1 2026 sales of $262 million out of ~$8 billion total product sales.; Trend: Increased 188% year-over-year in Q1 2026.
IMDELLTRA — Mix: ~3.2%; Source: Q1 2026 sales of $258 million out of ~$8 billion total product sales.; Trend: n/m, strong adoption.
PAVBLU — Mix: ~3.5%; Source: Q1 2026 sales of $280 million out of ~$8 billion total product sales.; Trend: n/m, adoption expanding.
BLINCYTO — Mix: ~5.2%; Source: Q1 2026 sales of $415 million out of ~$8 billion total product sales.; Trend: Increased 12% year-over-year in Q1 2026.
TAVNEOS — Mix: ~1.5%; Source: Q1 2026 sales of $119 million out of ~$8 billion total product sales.; Trend: Up 32% year-over-year in Q1 2026.
Product Brands: Repatha
EVENITY
TEZSPIRE
UPLIZNA
IMDELLTRA
MariTide
Olpasiran
Prolia
XGEVA
TEPEZZA
TAVNEOS
Otezla
BLINCYTO
PAVBLU
Enbrel
Neulasta
Aranesp
KYPROLIS
Nplate
Vectibix
MVASI
Parsabiv
EPOGEN
KANJINTI
Aimovig
AMGEVITATM
Sensipar/Mimpara
NEUPOGEN
IMLYGIC
Corlanor
AVSOLA
Xaluritamig
Dazodalibep

Bull / Bear Details

Amgen Inc. exhibits robust growth, driven by a diversified portfolio and a rapidly advancing pipeline, notably MariTide for obesity and Olpasiran for cardiovasc

Thesis

Amgen Inc. exhibits robust growth, driven by a diversified portfolio and a rapidly advancing pipeline, notably MariTide for obesity and Olpasiran for cardiovascular disease. Strong Q1 2026 performance and raised guidance signal successful navigation of patent expirations. However, ongoing biosimilar competition for key products and significant tax litigation pose material risks. The bull case remains compelling as of 2026-07-26, supported by pipeline execution and growth driver momentum.

Bull case

Amgen's diversified portfolio continues to deliver strong performance, with its six key growth drivers (Repatha, EVENITY, TEZSPIRE, rare disease, innovative oncology, and biosimilars) collectively generating 70% of sales and growing 24% year-over-year in Q1 2026. This broad-based momentum, including Repatha's 34% growth and UPLIZNA's 188% surge, effectively offsets patent expirations and underpins sustained revenue expansion.
The late-stage pipeline, particularly MariTide, represents a potential paradigm shift in obesity and type 2 diabetes treatment. New Phase III studies evaluating switching from weekly injectables to every 8- or 12-week dosing, alongside positive 3-step dose escalation data improving tolerability, strengthen its differentiated profile for long-term persistence and market adoption. Olpasiran's progress and new Lp(a) testing guidelines also enhance the cardiometabolic pipeline.
Amgen is significantly leveraging artificial intelligence and data science across its enterprise, accelerating R&D (e.g., 50% faster antibody lead optimization, up to threefold improvement in clinical trial enrollment) and optimizing manufacturing (e.g., reduced production line clearance time). This strategic integration of AI enhances long-term innovation, operational efficiency, and competitive advantage.

Bear case

Amgen anticipates accelerated sales erosion for key products like Prolia and Xgeva, which combined saw a 32% year-over-year decrease in Q1 2026. This significant decline, driven by increased competition from multiple biosimilars, is expected to continue over the remainder of 2026, necessitating continuous pipeline success to replace lost revenue.
Regulatory and pipeline risks persist, highlighted by the FDA's proposed withdrawal of TAVNEOS and the temporary pause in enrollment for subcutaneous BLINCYTO studies due to inflammatory reactions. Additionally, the decision to discontinue development of AMG 193 underscores the inherent uncertainties and potential setbacks in drug development.
Amgen faces substantial financial risk from ongoing tax litigation with the IRS for 2010-2015 and a new draft notice of proposed adjustment for 2016-2018. These disputes, primarily related to profit allocation with Puerto Rico, could result in material financial adjustments if not resolved favorably, impacting future earnings.

Bull / Bear Case

Bear Case: Amgen faces significant near-term headwinds from accelerated sales erosion of mature blockbusters like Prolia and Xgeva, which declined 32% in Q1 2026 due to biosimilar competition, a trend expected to accelerate. Regulatory risks, including the FDA's proposed withdrawal of TAVNEOS and a temporary pause in subcutaneous BLINCYTO studies, add uncertainty. Critically, substantial financial risk from ongoing IRS tax litigation for multiple years, with a new draft notice for 2016-2018, could materially impact financial statements, creating a significant overhang on the stock.
Bull Case: Amgen's robust Q1 2026 performance, with 24% growth from its six key drivers (Repatha, EVENITY, TEZSPIRE, rare disease, innovative oncology, and biosimilars), demonstrates successful navigation of patent expirations. The late-stage pipeline, particularly MariTide for obesity and type 2 diabetes, offers a paradigm-shifting opportunity with differentiated less-frequent dosing and improved tolerability, supported by positive early data. Olpasiran further strengthens the cardiometabolic franchise. Strategic AI integration is accelerating R&D and manufacturing efficiency. Management's raised 2026 guidance and strong pipeline execution underpin sustained long-term growth and shareholder value.
More Compelling & Why: Bear. Given the recent 13.49% stock appreciation post-earnings, Amgen's Price-to-Earnings (P/E) ratio has likely expanded, potentially making it less attractive relative to the immediate, quantifiable risks. The accelerated sales erosion of Prolia and Xgeva, coupled with the substantial IRS tax litigation, presents more certain near-term financial headwinds. My view would flip to Bull with a favorable resolution of the IRS tax disputes and initial, de-risking Phase III data for MariTide that clearly demonstrates superior differentiation and market potential.

Key Factors5 rows

Key Factor	Why It Matters	What To Watch	What It Signals	Where/How To Track	Free Alt Data	Paid Alt Data
Initial data readouts from MariTide Phase III SWITCH study and long-term maintenance studies	These studies are crucial for establishing MariTide's differentiated profile of less frequent dosing and favorable tolerability, which could drive significant market adoption and long-term persistence, validating the bullish GLP-1 thesis.	Announcement of top-line results, efficacy (e.g., change from baseline body weight after 52 weeks in SWITCH study), and tolerability data (e.g., rates of nausea and vomiting with 3-step dose escalation).	Bullish: Positive data demonstrating superior convenience (less frequent dosing) with comparable or superior efficacy and tolerability compared to weekly injectables. Bearish: Data showing no significant differentiation in convenience, efficacy, or tolerability, or unexpected safety signals.	Company press releases, investor presentations, scientific conferences (e.g., American Diabetes Association Annual Meeting, AHA), SEC filings (10-Q, 8-K). Expected in late 2026 or 2027.	ClinicalTrials.gov for study status updates, medical news outlets, analyst reports.	IQVIA: Prescription trends for GLP-1s (post-launch), EvaluatePharma: MariTide sales forecasts.
Rate of accelerated sales erosion for Prolia and Xgeva due to increased biosimilar competition	Prolia and Xgeva are significant revenue contributors. Accelerated erosion exceeding expectations could significantly offset growth from newer products, impacting overall revenue and profitability, posing a key downside risk.	Q2 2026 earnings report (expected late July/early August 2026) and subsequent quarterly reports. Monitor year-over-year percentage change and absolute sales decline for Prolia and Xgeva.	Bearish: Prolia and Xgeva combined sales decline exceeding management's 'accelerated sales erosion' expectations (e.g., significantly worse than Q1's 32% YoY decrease) or leading to a downward revision of overall 2026 revenue guidance.	Amgen's quarterly earnings releases, investor conference calls, SEC filings (10-Q).	Industry reports on biosimilar market share, news on new biosimilar launches.	IQVIA: Denosumab biosimilar market share and prescription data, EvaluatePharma: Sales forecasts for Prolia/Xgeva.
Amgen's achievement of raised 2026 revenue and non-GAAP EPS guidance	Achieving or exceeding the raised guidance confirms the company's ability to successfully navigate patent expirations with growth drivers and pipeline assets, reinforcing investor confidence and the overall bullish investment thesis.	Q2 2026 earnings report (expected late July/early August 2026) and subsequent quarterly reports. Monitor reported total revenues and non-GAAP EPS against the stated full-year guidance ranges of $37.1B-$38.5B and $21.70-$23.10, respectively.	Bullish: Q2 2026 results and/or updated full-year outlook indicate performance tracking towards or above the upper end of the raised guidance. Bearish: Q2 2026 results or updated outlook suggest performance tracking below the lower end of the raised guidance, or a subsequent guidance reduction.	Amgen's quarterly earnings releases, investor conference calls, SEC filings (10-Q).	Financial news websites, analyst consensus estimates (e.g., Yahoo Finance, Reuters).	Refinitiv Eikon: Consensus estimates tracking, earnings transcripts analysis.
Resolution of FDA's proposed withdrawal of Tavneos (avacopan) approval	Tavneos is an important medicine for ANCA-associated vasculitis. A mandated withdrawal would result in a complete loss of sales for this product and could negatively impact Amgen's reputation and future regulatory interactions.	Official communication from Amgen or the FDA regarding Tavneos's regulatory status, including a decision on withdrawal or a path forward for continued market access.	Bullish: FDA reverses its proposed withdrawal or reaches an agreement with Amgen for continued market access without significant restrictions. Bearish: FDA mandates withdrawal of Tavneos, or Amgen voluntarily withdraws the product, leading to cessation of sales.	Company press releases, SEC filings (8-K, 10-Q), FDA announcements.	FDA website for drug approvals/withdrawals, medical news outlets.	AdisInsight: Regulatory status updates for Tavneos, KOL surveys on physician sentiment.
Resolution of IRS tax litigation for 2010-2015 and 2016-2018 tax years	These tax disputes, primarily related to profit allocation with Puerto Rico, pose a significant financial risk. An unfavorable resolution could lead to material financial adjustments, impacting earnings and cash flow.	Official announcements from Amgen regarding the tax court decision for 2010-2015 and updates on the status of the 2016-2018 NOPA dispute, including any settlement or further IRS actions.	Bullish: Favorable resolution of the tax disputes, leading to no material financial impact or a lower-than-expected liability. Bearish: Unfavorable ruling or sustained adjustments that result in a material negative impact on financial statements, exceeding current tax reserves.	Amgen's SEC filings (10-Q, 10-K), company press releases. Decision for 2010-2015 expected no earlier than H2 2026.	Tax court public records (if available), financial news outlets covering corporate tax litigation.	Bloomberg Terminal: Tax litigation news and analysis, legal databases for case updates.

Key Reported Metrics, Reratings Triggers & Results3 rows

This aggregate metric highlights the performance of Amgen's most important and rapidly growing products, demonstrating the company's ability to generate signifi

Key reported metrics			Rerating thresholds
Metric	Last period	Why it matters	What's needed for rerating	Rerating context	Earnings date
Key Growth Drivers Sales (Aggregate)	24%	This aggregate metric highlights the performance of Amgen's most important and rapidly growing products, demonstrating the company's ability to generate significant revenue from its innovative portfolio and offset declines from mature assets.	The Key Growth Drivers Sales (Aggregate) metric needs to hit 25% year-over-year growth or higher in Q2 2026. This would demonstrate an acceleration from the 24% growth observed in Q1 2026, signaling even stronger momentum from Amgen's innovative portfolio and its ability to effectively offset declines from mature products.	Achieving 25%+ growth in key drivers validates Amgen's strategy of leveraging its innovative portfolio and pipeline to navigate patent expirations and biosimilar competition. It reinforces confidence in sustained revenue expansion, supports the raised 2026 guidance, and could lead to upward valuation revisions and a stronger competitive position.	2026-08-04
Total Product Sales	4%	This metric reflects Amgen's overall financial performance and its ability to grow despite competitive pressures and product declines. It indicates the effectiveness of its diversified portfolio and pipeline, and investors will monitor this for alignment with 2026 guidance.	Amgen Inc. (AMGN) needs to report Q2 2026 Total Product Sales growth of 5% year-over-year or higher. This would significantly exceed the current analyst consensus of 2.94% for Q2 2026 and surpass the upper end of the company's revised full-year 2026 revenue growth guidance (approximately 4.6% based on the high end of $38.5 billion and 2025 revenue of $36.8 billion). It would also be closer to the Q1 2026 actual growth of 5.8-6%, signaling sustained momentum.	Hitting this threshold demonstrates Amgen's ability to sustain robust growth, validating its diversified portfolio and pipeline, especially MariTide, despite biosimilar competition. This would significantly exceed current low expectations, reinforcing the bull case and potentially leading to upward valuation revisions and a stronger competitive position.	2026-08-04
Prolia and Xgeva Sales	-32%	This metric is crucial as it represents a significant drag on overall revenue due to accelerated biosimilar competition. Its decline rate directly impacts Amgen's ability to achieve its full-year guidance and manage patent expirations.	Prolia and Xgeva combined sales need to show a year-over-year decline of less than 32% in Q2 2026. This would indicate that the anticipated accelerated sales erosion due to biosimilar competition is not as severe as expected, or that Amgen is managing the competitive landscape more effectively than in Q1 2026.	This metric is crucial as it represents a significant drag on overall revenue due to accelerated biosimilar competition. A decline less than 32% would alleviate pressure on Amgen's overall revenue, demonstrating effective management of patent expirations and supporting the company's ability to achieve its raised full-year guidance.	2026-08-04

Key Questions

Will the initial data readouts from MariTide's Phase III SWITCH study and long-term maintenance studies confirm its differentiated profile of strong efficacy, f

Will the initial data readouts from MariTide's Phase III SWITCH study and long-term maintenance studies confirm its differentiated profile of strong efficacy, favorable tolerability with 3-step dose escalation, and convenient every 8- or 12-week dosing, thereby driving significant market adoption and validating its 'new paradigm' potential?

Question 2: Can Amgen Inc. successfully achieve its raised 2026 revenue and non-GAAP EPS guidance by effectively offsetting accelerated sales erosion from Prolia and Xgeva (and Otezla) with sustained strong performance from its key growth drivers and other pipeline assets?
Question 3: What will be the outcome of Amgen's ongoing tax litigation with the IRS for the 2010-2015 tax years and the newly received draft notice of proposed adjustment for 2016-2018, and what will be the material financial impact on the company's financial statements?

Earnings Transcript Summary2 rows

2026-04-30 · 2026Q1 Earnings Call

3 Things Management Is Most Focused On	Call Takeaway & Tone	Prior Quarter'S Y/Y Growth By Segment	3 Things Analysts Most Pressed On (And Mgmt Responses)	Revenue Segments
1. Achieving 2026 objectives as a 'springboard year': Management emphasized that 2026 is a year where rapidly growing products are expected to offset patent expirations and increased competition, while next-generation molecules progress through the R&D pipeline, setting the stage for sustained long-term growth. 2. Advancing the MariTide program: There is a strong focus on disciplined data generation and execution for MariTide, including new Phase III studies to evaluate switching from weekly injectables to every 8- or 12-week schedules and for weight maintenance, highlighting its potential as a differentiated treatment for obesity and type 2 diabetes. 3. Leveraging artificial intelligence and data science: Management is focused on embedding new capabilities across the company by applying AI and data science to accelerate drug discovery, optimize manufacturing processes, improve clinical trial enrollment, and enhance regulatory filing preparation.	The overall takeaway of the call was highly positive and confident. Management expressed satisfaction with a strong first quarter performance, reinforcing their outlook for 2026 as a 'springboard year' for future growth. They highlighted the robust momentum of their 6 key growth drivers, which collectively generated 70% of sales and grew 24% year-over-year. A significant theme was the advancement of the MariTide program, with new Phase III studies announced to evaluate switching from weekly injectables and long-term maintenance, emphasizing its differentiated profile. Management also underscored the increasing importance and successful integration of artificial intelligence and data science across R&D and operations. The tone was optimistic, with management raising 2026 guidance for both revenue and non-GAAP earnings per share, indicating confidence in their ability to grow through a period of patent expiration and deliver attractive performance.	Overall sales growth was 10% year-over-year in Q4 2025, decelerating to 4% in Q1 2026. Repatha sales grew 36% year-over-year in Q4 2025, decelerating to 34% in Q1 2026. EVENITY sales grew 34% year-over-year in Q4 2025, decelerating to 27% in Q1 2026. TEZSPIRE sales grew 52% year-over-year in Q4 2025, decelerating to 20% in Q1 2026. Prolia sales increased 1% year-over-year in Q4 2025, significantly decelerating to a 32% decrease (combined with Xgeva) in Q1 2026. The rare disease portfolio sales grew 19% year-over-year in Q4 2025, accelerating to 25% in Q1 2026. UPLIZNA sales grew 73% year-over-year in Q4 2025, significantly accelerating to 188% in Q1 2026. TEPEZZA sales grew 3% year-over-year in Q4 2025, significantly accelerating to 29% in Q1 2026. TAVNEOS sales grew 62% year-over-year in Q4 2025, decelerating to 32% in Q1 2026. The innovative oncology portfolio sales grew 11% year-over-year in Q4 2025, accelerating to 25% in Q1 2026. BLINCYTO sales grew 28% year-over-year in Q4 2025, decelerating to 12% in Q1 2026. The biosimilar portfolio sales grew 37% year-over-year in Q4 2025, decelerating to 14% in Q1 2026. Year-over-year growth for IMDELLTRA and PAVBLU was not explicitly stated for Q4 2025 in percentage terms, making a direct comparison difficult.	1. MariTide SWITCH studies design and maintenance opportunity: Analysts inquired about the design of the MariTide SWITCH studies, specifically the dosing frequencies (monthly, every 2 months, every 3 months) and whether they are looking for superiority or non-inferiority, as well as the significance of the maintenance opportunity. Management responded that the SWITCH study will have 300 subjects with obesity or overweight, with a run-in on weekly semaglutide or tirzepatide, then switching to MariTide every 8-week or quarterly. The primary endpoint will be change from baseline body weight after 52 weeks. They also highlighted the importance of understanding how to convert from weekly agents to a more convenient regimen and how to modify the dose interval for maintenance. 2. IMDELLTRA's future in earlier lines of therapy and the real-time clinical trial pilot program: Analysts asked about the next steps for IMDELLTRA, particularly its opportunity in earlier lines of therapy and its selection for the real-time clinical trial pilot program. Management stated that IMDELLTRA is being advanced into frontline induction as well as frontline induction and maintenance in extensive-stage small cell lung cancer, with studies rapidly progressing. Regarding the real-time clinical trial, they explained it's a collaboration with the FDA to characterize IMDELLTRA in a real-world setting using electronic health records and real-time data capture, aiming to improve trial efficiency and patient access. 3. Olpasiran's trial design and the impact of background therapies (GLP-1 or PCSK9): Analysts questioned whether background therapies like GLP-1s or PCSK9s would impact Olpasiran's trial design or competitor trial designs. Management affirmed the well-designed OCEAN(a) study for high-risk Lp(a) patients, noting that Olpasiran delivers greater than 95% reduction in Lp(a) with quarterly dosing. They emphasized that GLP-1 medicines, statins, or Repatha (PCSK9) do not meaningfully reduce Lp(a) levels, making Olpasiran's targeted therapy crucial for this independent risk factor.	Overall product sales grew 4% year-over-year. The 6 key growth drivers (Repatha, EVENITY, TEZSPIRE, rare disease, innovative oncology, and biosimilars portfolios) collectively delivered 24% year-over-year sales growth. Repatha sales increased 34% year-over-year. EVENITY sales increased 27% year-over-year. TEZSPIRE sales grew 20% year-over-year. Prolia and XGEVA combined sales decreased 32% year-over-year. The rare disease portfolio grew 25% year-over-year. UPLIZNA sales increased 188% year-over-year. TEPEZZA sales grew 29% year-over-year. TAVNEOS sales were up 32% year-over-year. The innovative oncology portfolio grew 25% year-over-year. IMDELLTRA delivered $258 million in first quarter sales. BLINCYTO sales increased 12% year-over-year. The biosimilar portfolio delivered 14% year-over-year growth. PAVBLU delivered $280 million in first quarter sales.

2026-02-03 · 2025Q4 Earnings Call

3 Things Management Is Most Focused On	Call Takeaway & Tone	Prior Quarter'S Y/Y Growth By Segment	3 Things Analysts Most Pressed On (And Mgmt Responses)	Revenue Segments
1. Driving growth from key products and pipeline: Management highlighted 14 products achieving blockbuster status, 13 with double-digit growth, and 18 achieving record results in 2025. They specifically called out Repatha, Evenity, and TestSpire as growing over 30% year-over-year and being "growth drivers not just for 2026, but for the rest of the decade." They also emphasized the rare disease, innovative oncology, and biosimilars portfolios. 2. Advancing a robust and differentiated pipeline, especially Meritide and opaziran: Management expressed strong confidence in Meritide for obesity, type 2 diabetes, and related conditions, emphasizing its potential for strong efficacy, favorable tolerability, and infrequent dosing (monthly, bimonthly, or quarterly). They also highlighted opaziran for elevated Lp(a) as an opportunity to expand leadership in cardiometabolic disease. 3. Disciplined execution, data generation, and financial discipline: Management repeatedly mentioned "strong disciplined execution across R&D" and "disciplined data generation" for 2026. Peter Griffith also underscored "rigorous management of working capital" and "maintaining rigorous financial discipline," while investing in the business and returning capital to shareholders.	The call conveyed a positive and confident tone. Management highlighted strong operational performance in 2025, with double-digit revenue and EPS growth, and expressed excitement about carrying this momentum into 2026. Key takeaways included the robust performance of established growth drivers (Repatha, Evenity, TestSpire), the significant potential of the late-stage pipeline, particularly Meritide for obesity and diabetes, and opaziran for cardiovascular disease, and the continued strength of their rare disease, innovative oncology, and biosimilars portfolios. Management emphasized disciplined execution, data generation, and financial rigor. While analysts pressed on competitive landscapes and pipeline specifics, management's responses consistently reinforced their strong market position, differentiated assets, and confidence in future growth.	Overall revenues: 12% year over year. Repatha: 40% year over year. EVENITY: 36% year over year. TEZSPIRE: 40% year over year. TEPEZZA: 15% year over year. UPLIZNA (EPLISMA): 46% year over year. TAVNEOS (TADNIA): 34% year over year. Biosimilar portfolio: 52% year over year. BLINCYTO: Double-digit growth (specific percentage not found). Prolia: No specific y/y growth percentage found for Q3 2025. Innovative oncology portfolio: Not explicitly stated as a combined segment, but Imdeltra had 33% sequential growth. Otezla: An intangible asset impairment charge of $400 million was recorded in Q3 2025, no y/y growth percentage found. Rare disease portfolio: Not explicitly stated as a combined segment, but individual rare disease products like Uplizna showed strong growth.	1. Meritide's potential and dosing frequency (and the broader obesity portfolio): Analysts inquired about Amgen's overall obesity portfolio and the potential for Meritide's less frequent than monthly dosing. Management responded by emphasizing Meritide's potential as a "paradigm-changing therapy" with strong efficacy, good tolerability, and the ability to offer monthly, every eight-week, or quarterly dosing for maintenance, which they believe addresses a major unmet need and patient dissatisfaction with weekly GLP-1s. They also mentioned other clinical and preclinical assets in their obesity pipeline. 2. Aplisna's market opportunity and expansion into new indications (IgG4-related disease and gMG): Analysts asked about the size of the IgG4-related disease population and Aplisna's early uptake and role in the crowded generalized myasthenia gravis (gMG) market. Management acknowledged the evolving understanding of the IgG4-related disease epidemiology and expressed satisfaction with Aplisna's strong uptake across specialties. For gMG, they noted strong early interest from both bio-naive and switch patients, highlighting its upstream B-cell mechanism, safety profile, and twice-yearly dosing convenience as key differentiators. They also discussed the rationale for expanding Aplisna into autoimmune hepatitis and CIDP based on its mechanism. 3. Repatha's strategy amidst potential new PCSK9 competitors (like Merck's oral PCSK9): Analysts questioned how Amgen plans to maintain Repatha's leadership, especially with the potential launch of oral PCSK9 inhibitors, and the evolving role of primary care in prescribing. Management stressed the "landmark data" from the Vesalius CV trial, which demonstrated Repatha's ability to reduce the risk of first major cardiovascular events in high-risk primary and secondary prevention patients. They asserted that Repatha is the "most evidence-backed therapy in the PCSK9 class" and that new competitors "will not have the data package and profile that Repatha has established." They also noted that while primary prevention prescriptions were around 40%, they expect this to grow, with strong interest from both cardiologists and primary care physicians in the Vesalius data.	Overall sales growth: 10% year over year. Repatha sales: 36% year over year. Evenity sales: 34% year over year. Rare disease portfolio sales: 14% year over year (full year), 19% (Q4). EPLISMA sales: 73% year over year. TEPEZZA sales: 3% year over year. TADNIA sales: 62% year over year. TestBio (TESSPIRE) sales: 52% year over year. Otezla sales: 7% year over year. Innovative oncology portfolio sales: 11% year over year. BLINCYTO sales: 28% year over year. Biosimilar portfolio sales: 37% year over year. Prolia sales: 1% year over year. Imdeltro full-year sales: $627 million (y/y growth not specified). PAV Blue 2025 sales: $700 million (y/y growth not specified).

Transcript Tidbits2 rows

2026-04-30

About Expanding Eligible Market	About Competition	About The Broader Industry	Where Things Are Headed	Updates On Theme	Broader Themes Emerging	Bullish-Leaning Quotes (Short)	Bearish-Leaning Quotes (Short)	Hiring
Amgen expects to grow through patent expirations and competition by leveraging its portfolio of innovative medicines and biosimilars to meet patient needs. MariTide's Phase III studies are evaluating switching from weekly injectables to an every 8- or 12-week schedule and weight maintenance on a 4 or 6 injections per year schedule, aiming to improve long-term treatment persistence. Repatha's market is expanding due to updated ACC/AHA guidelines reinforcing earlier risk identification and lower LDL-C targets, and a simplified cash pay option in the U.S. EVENITY has a significant opportunity to expand its market as over 90% of 2 million women at very high fracture risk remain untreated. TEZSPIRE's new indication for coexisting chronic rhinosinusitis with nasal polyps is expanding its reach. UPLIZNA is seeing strong uptake in gMG across bio-naive and switch patients, with broad access, and is expected to initiate two pivotal Phase III studies in autoimmune hepatitis and chronic inflammatory demyelinating polyneuropathy. TEPEZZA's on-body injector will enable administration at additional sites of care and global launches are planned for 2026 and beyond. IMDELLTRA is expanding patient access through efforts to remove operational barriers in community settings and is being advanced into earlier lines of therapy for small cell lung cancer. Olpasiran's potential market is growing with new ACC/AHA lipid guidelines recommending broader Lp(a) testing.	Amgen anticipates accelerated sales erosion for Prolia and Xgeva over the remainder of 2026 due to increased competition from multiple biosimilars. MariTide aims to differentiate itself from existing obesity medicines by offering less frequent dosing (monthly, every 8- or 12-weeks) and favorable tolerability, addressing treatment burden and persistence issues. Repatha is highlighted as the only PCSK9 inhibitor with positive outcomes data in both high-risk primary and secondary prevention patients. Olpasiran targets Lp(a), an independent risk factor not meaningfully reduced by GLP-1 medicines, statins, or PCSK9 inhibitors. Amgen acknowledges coming later into the GLP-1 market but sees an opportunity to convert patients from weekly agents to MariTide's more convenient regimen, especially for those dissatisfied with current therapies.	The broader industry is experiencing a 'convergence of technology and biology,' with significant advancements in artificial intelligence being applied across Amgen. This includes leveraging AI to accelerate drug discovery and therapeutic development, optimize manufacturing, and improve customer engagement. Tangible benefits are being seen in integrated multi-omics data resources for target identification, a 50% acceleration in antibody lead optimization, and up to a threefold improvement in clinical trial enrollment rates through proprietary site selection models. Large language models and Agentic AI are showing promising results in regulatory filing preparation, and AI-enabled automation has reduced production line clearance time at a manufacturing site from approximately 30 minutes to about 2 minutes per batch run.	Amgen describes 2026 as a 'springboard year for future growth,' with rapidly growing products expected to offset patent expirations and increased competition, while next-generation molecules progress through the R&D pipeline for sustained long-term growth. The company's focus for the year is on disciplined data generation and execution across important Phase III programs. MariTide is emerging as a new paradigm for obesity, diabetes, and related conditions, with a focus on high-quality clinical data for future regulatory filings. Amgen is raising its 2026 guidance ranges for total revenues to $37.1 billion to $38.5 billion and non-GAAP earnings per share to between $21.70 and $23.10, reflecting confidence that emerging growth drivers will offset legacy brand declines. The company remains focused on delivering sustained long-term growth, advancing innovation, and maintaining rigorous financial discipline.	GLP1	The 'convergence of technology and biology' is a significant broader theme, with Amgen actively integrating artificial intelligence (AI) across its enterprise. This includes AI for accelerating drug discovery and development, optimizing manufacturing processes, and enhancing productivity for colleagues. Specific applications mentioned are multi-omics data resources for target identification, accelerated antibody lead optimization, improved clinical trial enrollment through AI-enabled site selection models, and leveraging large language models and Agentic AI for regulatory filing preparation. AI-enabled automation has also significantly reduced production line clearance time in manufacturing.	We had a strong first quarter and are well positioned to achieve our objectives for the year. Our confidence in MariTide as a differentiated treatment for obesity, type 2 diabetes and obesity-related conditions continues to build. Together, they generated 70% of our sales in the quarter and grew in aggregate by 24%. MariTide is emerging as a new paradigm for patients with obesity, diabetes and related conditions as a well-tolerated first monthly or less frequently administered medicine. We're raising our 2026 guidance ranges for both revenue and non-GAAP earnings per share.	offset the financial impact of patent expirations and increased competition. Erosion since loss of exclusivity remains in line with our expectations, and we anticipate accelerated sales erosion over the remainder of 2026, driven by increased competition from multiple biosimilars. As publicly disclosed, the FDA proposed to withdraw the approval of TAVNEOS. We've taken the decision to discontinue development of AMG 193. If sustained in full, the adjustments set forth in the draft NOPA could have a material impact on our financial statements.	EVENITY's growth has been supported by an expanded field force. Jay Bradner is taking over the leadership of AI and data transformation across the business at the enterprise level, following the retirement of David Reese, who was Amgen's first Chief Technology Officer and helped attract Jay Bradner. Amgen colleagues are using AI to enhance productivity.

2026-02-03

About Expanding Eligible Market	About Competition	About The Broader Industry	Where Things Are Headed	Updates On Theme	Broader Themes Emerging	Bullish-Leaning Quotes (Short)	Bearish-Leaning Quotes (Short)	Hiring
Amgen Inc. sees significant growth opportunities by reaching new patients, expanding into additional geographies, and launching new indications for its rare disease portfolio. Repatha targets over 100 million people globally who still need effective LDL cholesterol lowering, with new data strengthening its position for both high-risk primary and secondary prevention, potentially leading to updated clinical guidelines. Evenity has a clear opportunity for growth as nearly 90% of the 2 million women at very high risk of fracture remain untreated. Uplisna received FDA approval for generalized myasthenia gravis and European Commission approval for IgG4-related disease in 2025, with strong early physician response and growing uptake across various specialties. Meritide is expanding its clinical landscape across obesity-related conditions, including two Phase III sleep apnea studies, and offers the potential for monthly, every other month, or even quarterly dosing. TEPEZZA plans to launch in additional international markets in 2026 and is expanding treatment to lower clinical activity score thyroid eye disease patients. Imdeltra is being advanced as combination therapy in frontline extensive-stage small cell lung cancer and in a Phase III study for limited-stage small cell lung cancer.	Amgen Inc. anticipates accelerated sales erosion for Prolia in 2026 due to increased competition from multiple biosimilars launched globally. Otezla is expected to face sales erosion from unfavorable pricing in the U.S. and generic launches, particularly in the EU. The company acknowledges anticipated declines from increased denosumab biosimilar competition and price declines for certain other products in 2026. Despite new entrants, Amgen Inc. asserts that Repatha will maintain its leadership due to its established data package and profile, which competitors will not have. Meritide is highlighted as standing alone in late-stage development for obesity and type two diabetes, offering strong efficacy and favorable tolerability at less frequent dosing compared to dozens of potential daily oral and weekly injectable medicines. Amgen Inc.'s biosimilars portfolio, which generated $3 billion in sales in 2025, is poised for growth with the next wave of launches, including ABP-206 (Opdivo biosimilar) and ABP-234 (Keytruda biosimilar). PAV Blue, a biosimilar to EYLEA, continues to gain momentum and is competing effectively against the innovator and anticipated future entrants.	The broader industry is experiencing a significant trend in the 'convergence of technology and life science,' which Amgen Inc. believes will have a substantial impact on how medicines are discovered, developed, and commercialized. Amgen Inc. is leveraging AI across its value chain to accelerate therapeutic discovery and late-stage development, optimize manufacturing, and improve customer engagement, driving productivity at speed and scale.	Amgen Inc. expects 2026 to be a 'springboard year for future growth,' with anticipated total revenues in the range of $37 billion to $38.4 billion and non-GAAP earnings per share between $21.6 to $23. The company highlights six areas of momentum for 2026, including Repatha, Evenity, and TestSpire, which are expected to be growth drivers for the rest of the decade. Amgen Inc. plans for 2026 to be a year of disciplined data generation from exciting Phase II and Phase III programs. The combination of Repatha, opaziran, and Meritide is seen as a compelling set of cardiometabolic medicines to expand leadership in serious chronic diseases well into the next decade. The company remains focused on delivering sustained long-term growth and creating value for patients and shareholders by advancing innovation in areas of high unmet medical need and maintaining rigorous financial discipline.	GLP1	The 'convergence of technology and life science' is a broader theme emerging, with Amgen Inc. actively 'leveraging AI across the value chain to accelerate therapeutic discovery and late-stage development, optimize manufacturing, and improve customer engagement.'	Amgen Inc. delivered strong operational performance across the board in 2025. 14 of our products achieved blockbuster status with sales of a billion dollars or more. The strength of that broad portfolio enabled us to post double-digit growth in revenues and earnings per share for 2025. Meritide stands alone as the only therapy in late-stage development to offer the paradigm-changing prospect of strong efficacy and favorable tolerability at monthly, every other month, or even quarterly dosing. We expect our 2026 total revenues in the range of $37 billion to $38.4 billion and non-GAAP earnings per share between $21.6 to $23. positioning 2026 as a springboard year for future growth.	In 2026, we expect accelerated sales erosion driven by increased competition as multiple biosimilars have launched globally. For 2026, We expect sales erosion driven by unfavorable pricing in The U.S., and generic launches particularly in The EU. We recently announced the decision to terminate the role rocotinlimab development and commercialization collaboration with Kewa Kirin. We have decided not to pursue regulatory approval for bimirtuzumab. The FDA requested a voluntary withdrawal on January 16. We were surprised by this.

NotesTable

Date	Comment	Comment Type	Comment Sentiment	Link	Price Reaction
2026-02-03	Amgen reported strong Q4 2025 results with double-digit revenue and EPS growth, fueled by key products and an optimistic 2026 outlook. The company highlighted pipeline momentum, particularly for Meritide in obesity. Despite biosimilar competition and a Tavneos withdrawal request, the market reacted very positively, with the stock gaining 13.51% (t+2 days), significantly outperforming the SPY.	Earnings Transcript	Mixed		+13.51% (vs SPY: +13.35%)

Upcoming Events7 rows

Catalyst ID	Estimated Timing	Estimated Date Start	Estimated Date End	Catalyst	Why It Matters	Ticker Or Theme Specific	Transcript Date	Source Type
AMGN_2e8df87c	August 19, 2026 (estimated)	2026-08-19	2026-08-19	Completion of the Phase III HZNP-DAZ-301 study for Dazodalibep in Sjogren's syndrome with moderate-to-severe systemic disease activity.	This is a key data collection milestone for a potential new treatment for Sjogren's disease, a condition with high unmet medical need, and could lead to future regulatory filings and market expansion.	Ticker	2026-04-30	earnings_transcript
AMGN_b978ca77	2026-09-07 (Estimated)	2026-09-07	2026-09-07	Initiation of the Phase 2/3 study (NCT07598825) for UPLIZNA (inebilizumab) in participants with autoimmune hepatitis.	This initiation represents the expansion of UPLIZNA into a new, significant autoimmune indication, broadening its potential therapeutic reach and future revenue streams.	Ticker	2026-04-30	earnings_transcript
AMGN_ce3d8cd2	Including preparing for Miratide's launch.	2026-01-01	2026-12-31	Preparations and potential launch of Meritide, a novel therapy for obesity, type 2 diabetes, and related conditions.	Meritide is a key growth driver for Amgen. Its successful launch and market penetration would significantly impact Amgen's revenue and competitive position in the rapidly growing GLP-1 market.	Ticker	2026-02-03	earnings_transcript
AMGN_17b91ee0	study completion expected in 2026.	2026-07-01	2026-12-31	Completion of both Phase III studies for desodoliveb, a CD40 ligand targeting biotherapeutic, in Sjogren's disease.	Study completion is a critical step before data readout and potential regulatory filings, which could position desodoliveb as a significant treatment option in a challenging autoimmune condition.	Ticker	2026-02-03	earnings_transcript
AMGN_fe4d51bf	We will update you on those discussions as necessary.	2026-04-24	2026-12-31	Resolution of ongoing discussions with the FDA regarding TABNIO's (avacopan) following a voluntary withdrawal request related to primary endpoint result readjudication.	The outcome will determine the future commercial viability of TABNIO's, impacting Amgen's rare disease portfolio and potentially leading to a re-evaluation of the product's sales trajectory.	Ticker	2026-02-03	earnings_transcript
AMGN_f1821dd7	We plan to launch TEPEZZA in additional markets in 2026	2026-01-01	2026-12-31	Launch of TEPEZZA in additional international markets.	Expanding TEPEZZA's geographic reach will contribute to its global sales growth and further establish Amgen's presence in the thyroid eye disease market.	Ticker	2026-02-03	earnings_transcript
AMGN_a4f12076	2026 will be a year of disciplined data generation. From a number of exciting phase II and phase III programs that will pave the way for long-term growth at Amgen Inc.	2026-01-01	2026-12-31	Data generation and potential readouts from multiple ongoing Phase III clinical trials for Meritide in chronic weight management, ASCVD, heart failure, and sleep apnea.	Positive data from these late-stage trials could significantly enhance Amgen's competitive position in the rapidly expanding obesity and cardiometabolic markets, materially impacting future revenue guidance and valuation. Conversely, unfavorable outcomes would represent a significant setback.	Ticker	2026-02-03	earnings_transcript